After a chapter court docket accredited the sale of 23andMe’s property to a nonprofit led by the corporate’s co-founder and former CEO, Anne Wojcicki, the way forward for its huge trove of DNA information is barely starting to unfold. Wojcicki’s TTAM Analysis Institute gained the public sale to amass the genetic database, beating out Regeneron Prescribed drugs with a $305 million bid. The sale is predicted to shut after July 8, in response to a memo despatched by 23andMe to present and former prospects, marking the top of a chapter that started when the corporate filed for Chapter 11 chapter in March.
Wojcicki launched TTAM earlier this 12 months with the precise aim of preserving 23andMe’s genetic information of about 15 million customers out of the palms of third events like biotech agency Regeneron, which bid $256 million for the corporate’s property. Given the delicate nature of the information, 29 states pushed again in opposition to the switch by submitting a joint lawsuit in April.
Although TTAM’s web site stays naked bones, 23andMe’s buyer memo describes its mission as “continu[ing] the modern analysis and scientific discoveries that had been core to 23andMe, whereas increasing its lively conduct of medical analysis and academic actions to empower people to find out about their very own genomes and advance our information of human well being.”
The place Wojcicki comes from—and the place she’s headed
Wojcicki co-founded 23andMe in 2006 alongside Linda Avey and Paul Cusenza. In 2021, she took the corporate public by means of a reverse merger with a particular goal acquisition firm (SPAC). Simply two years later, a knowledge breach compromised the genetic info of seven million customers. In 2024, after a 98 % drop in market cap, Wojcicki tried to take the corporate non-public, however the board of administrators rejected the transfer.
TTAM has pledged to keep up 23andMe’s present privateness requirements, however issues round information safety stay widespread. In its buyer memo, 23andMe emphasised, “TTAM is legally obligated to keep up and honor the privateness insurance policies, consumer consents and information safety measures which were put in place by 23andMe.” Clients nonetheless can choose out of analysis or completely delete their information.
Although TTAM is structured as a nonprofit, some specialists stay skeptical. Erika Grey, pharmacist and founding father of ToolBox Genomics, pointed to Wojcicki’s monitor document. “When an organization goes public or brings in non-public fairness, the customers typically develop into insignificant and the main focus is the success of the inventory and development of the corporate,” she instructed Observer.
Earlier this 12 months, Nucleus Genomics thought-about bidding for 23andMe’s property however finally opted out. In contrast to 23andMe, Nucleus maintains all of its well being information in compliance with HIPAA requirements. TTAM has acknowledged it plans to repeatedly enhance its personal privateness insurance policies over time.
Past TTAM, Wojcicki can also be concerned in industrial actual property redevelopment in Los Altos, Calif. and in philanthropy by means of the Brin Wojcicki Basis, a three way partnership together with her ex-husband, Google co-founder Sergey Brin. The muse has contributed extensively to Parkinson’s analysis and Jewish-American humanitarian support.
